Exchange Traded Concepts LLC Purchases 22,809 Shares of Structure Therapeutics Inc. Sponsored ADR $GPCR

Key Points

• Exchange Traded Concepts LLC increased its stake in Structure Therapeutics by 58.6%, acquiring an additional 22,809 shares, bringing their total ownership to 61,732 shares valued at approximately $1.28 million.
• The stock has recently seen a 3.7% increase in value, opening at $24.45, with a market capitalization of $1.41 billion.
• Structure Therapeutics reported a quarterly EPS of ($0.36), missing analysts' expectations, with forecasts indicating an average EPS of ($0.82) for the current fiscal year.

Exchange Traded Concepts LLC boosted its position in shares of Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Free Report) by 58.6% during the 2nd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 61,732 shares of the company's stock after acquiring an additional 22,809 shares during the period. Exchange Traded Concepts LLC owned approximately 0.11% of Structure Therapeutics worth $1,280,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in the company. GF Fund Management CO. LTD. bought a new stake in shares of Structure Therapeutics in the 4th quarter valued at approximately $34,000. National Bank of Canada FI grew its stake in shares of Structure Therapeutics by 1,448.2% in the 1st quarter. National Bank of Canada FI now owns 2,957 shares of the company's stock valued at $51,000 after purchasing an additional 2,766 shares during the period. ANTIPODES PARTNERS Ltd grew its stake in shares of Structure Therapeutics by 310.7% in the 1st quarter. ANTIPODES PARTNERS Ltd now owns 4,247 shares of the company's stock valued at $74,000 after purchasing an additional 3,213 shares during the period. Parallel Advisors LLC bought a new stake in shares of Structure Therapeutics in the 2nd quarter valued at approximately $171,000. Finally, GAMMA Investing LLC boosted its holdings in shares of Structure Therapeutics by 663.8% in the 1st quarter. GAMMA Investing LLC now owns 8,776 shares of the company's stock worth $152,000 after acquiring an additional 7,627 shares in the last quarter. 91.78% of the stock is currently owned by institutional investors.

Structure Therapeutics Trading Up 3.7%

GPCR stock opened at $24.45 on Tuesday. The stock has a 50-day moving average price of $19.31 and a two-hundred day moving average price of $20.65. The stock has a market cap of $1.41 billion, a PE ratio of -23.29 and a beta of -1.89. Structure Therapeutics Inc. Sponsored ADR has a 1 year low of $13.22 and a 1 year high of $45.37.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last released its earnings results on Wednesday, August 6th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.28) by ($0.08). On average, analysts forecast that Structure Therapeutics Inc. Sponsored ADR will post -0.82 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several research analysts have recently commented on the company. HC Wainwright reduced their target price on Structure Therapeutics from $75.00 to $60.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. Guggenheim reduced their price objective on Structure Therapeutics from $92.00 to $90.00 and set a "buy" rating on the stock in a report on Thursday, August 7th. JMP Securities reduced their price objective on Structure Therapeutics from $89.00 to $87.00 and set a "market outperform" rating on the stock in a report on Thursday, August 7th. Lifesci Capital raised Structure Therapeutics to a "strong-buy" rating in a report on Monday, September 8th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $65.00 price objective on shares of Structure Therapeutics in a report on Monday, June 23rd. One equities research analyst has rated the stock with a Strong Buy rating and seven have issued a Buy rating to the company's stock. According to data from MarketBeat.com, the company has an average rating of "Buy" and an average price target of $68.67.

About Structure Therapeutics

Structure Therapeutics Inc, a clinical stage global biopharmaceutical company, develops and delivers novel oral therapeutics to treat a range of chronic diseases with unmet medical needs. The company's lead product candidate is GSBR-1290, an oral and biased small molecule agonist of glucagon-like-peptide-1 receptor, a validated G-protein-coupled receptors (GPCRs) drug target for type-2 diabetes mellitus and obesity.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.